<DOC>
	<DOCNO>NCT00016913</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Androgens stimulate growth prostate cancer cell . Drugs goserelin leuprolide may stop adrenal gland produce androgen . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy , hormone therapy , radiation therapy may kill tumor cell . PURPOSE : This phase II trial study give chemotherapy together hormone therapy radiation therapy treat patient locally advanced prostate cancer .</brief_summary>
	<brief_title>Chemotherapy , Hormone Therapy , Radiation Therapy Treating Patients With Locally Advanced Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility safety paclitaxel , estramustine , carboplatin , androgen ablation follow radiotherapy patient poor-prognosis locally advanced prostate cancer . - Determine progression-free survival time prostate specific antigen failure patient treat regimen . OUTLINE : This multicenter study . Patients receive paclitaxel IV 1 hour weekly ; oral estramustine three time day , five day week ; carboplatin IV 1 hour monthly . Treatment repeat every 4 week 4 course . Patients also receive gonadotropin-releasing hormonal therapy comprise either goserelin subcutaneously leuprolide intramuscularly monthly . Treatment repeat every 4 week 6 course . After completion chemotherapy , patient undergo radiotherapy daily week 17-24 . Treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 4 year . PROJECTED ACCRUAL : A total 60 patient accrue study within 1.5 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate one follow prognostic factor : Tx N0 , baseline prostate specific antigen ( PSA ) great 20 ng/mL , Gleason score least 7 T3b4 N0 , baseline PSA , Gleason score No pelvic lymph node disease require pelvic radiotherapy No metastatic disease bone scan , CT scan , MRI PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 1.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No significant cardiovascular disease No New York Heart Association class III IV congestive heart failure No active angina pectoris No myocardial infarction within past 6 month No history hemorrhagic thrombotic cerebral vascular accident No deep vein thrombosis within past 6 month Pulmonary : No pulmonary embolism within past 6 month Other : Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy prostate cancer No concurrent routine filgrastim ( GCSF ) sargramostim ( GMCSF ) Chemotherapy : No prior chemotherapy prostate cancer No concurrent anticancer chemotherapy Endocrine therapy : No 6 week prior androgen deprivation therapy No concurrent anticancer hormonal therapy except steroid adrenal failure and/or hormone nondiseaserelated condition ( e.g. , insulin diabetes ) Radiotherapy : See Disease Characteristics No prior radiotherapy prostate cancer No concurrent anticancer radiotherapy Surgery : At least 4 week since prior major surgery Other : No prior alternative therapy ( e.g. , PCSPES ) prostate cancer No concurrent alternative medicine ( e.g. , PCSPES saw palmetto ) large quantity vitamins No concurrent anticancer therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>